Chongqing Zhifei Biological Products (300122.SZ): Application for Clinical Trial of Pandemic Influenza Virus mRNA Vaccine Accepted

Chongqing Zhifei Biological Products (300122.SZ) announced that the company recently learned that the pandemic influenza virus mRNA vaccine developed by its wholly-owned subsidiary Anhui Zhifei Longcom Biopharmaceutical Co., Ltd. ("Zhifei Longcom") has received a drug clinical trial application acceptance notice (acceptance number: CXSL2601222) from the National Medical Products Administration. If no negative or questioning opinions are received from the Center for Drug Evaluation within 60 days from the date of acceptance, Zhifei Longcom may conduct clinical trials according to the submitted protocol. The pandemic influenza virus mRNA vaccine developed by Zhifei Longcom is intended for preventive vaccination against pandemic influenza. Vaccination with this vaccine can stimulate the body to produce immunity against pandemic influenza viruses. This product was developed on the basis of the company's independently established mRNA technology platform and offers the advantage of rapid response. Compared with traditional egg-based inactivated vaccines, the preparation cycle of mRNA vaccines is significantly shortened.